The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, ...

Dr. Peter Marks is being forced to resign from the FDA because the Trump administration does not want someone who is ...

(Reuters) -Peter Marks, the FDA's top vaccine official ousted by Robert F. Kennedy Jr. said the U.S. health secretary's team ...

Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports.

US biotech Novavax (Nasdaq: NVAX) is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April ...

While it’s not unusual for certain positions to turn over with a new administration, the number of senior-level FDA staffers ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%.

President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the ...

"Just where is that extensive 5000 word longform apology from Adam Cifu over at Sensible Medicine, begging forgiveness for ...

On the precipice of FDA approval, Novavax's Covid vaccine is now in limbo while a decision to approve or reject it is held up ...

Ousted FDA biologics and vaccine chief Peter Marks was asked to provide non-existent data on the risk from measles vaccines, ...